Page 57 - Haematologica March 2020

Seronegative antiphospholipid syndrome
10. Pastori D, Parrotto S, Vicario T, et al. Antiphospholipid syndrome and anticoagu- lation quality: a clinical challenge. Atherosclerosis. 2016;244:48-50.
11. Kearon C, Parpia S, Spencer FA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018;131(19): 2151-2160.
12. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242.
13. Pastori D, Bucci T, Triggiani M, et al. Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis. Autoimmun Rev. 2019;18(5):519-525.
14. Uthman I, Noureldine MHA, Ruiz-Irastorza G, Khamashta M. Management of antiphos- pholipid syndrome. Ann Rheum Dis. 2019;78(2):155-161.
15. Espinosa G, Rodriguez-Pinto I, Cervera R. Catastrophic antiphospholipid syndrome: an update. Panminerva Med. 2017;59(3): 254-268.
16. Espinosa G, Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol. 2015;11(10): 586-596.
17. Schreiber K, Radin M, Sciascia S. Current insights in obstetric antiphospholipid syn- drome. Curr Opin Obstet Gynecol. 2017;29(6):397-403.
18. Abreu MM, Danowski A, Wahl DG, et al. The relevance of "non-criteria" clinical man- ifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401-414.
19. Tektonidou MG, Ioannidis JP, Moyssakis I, et al. Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome. Ann Rheum Dis. 2001;60(1):43-48.
20. Roldan JF, Brey RL. Neurologic manifesta- tions of the antiphospholipid syndrome. Curr Rheumatol Rep. 2007;9(2):109-115.
21. Bucci T, Menichelli D, Pignatelli P, et al. Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review. J Alzheimers Dis. 2019;69(2):561-576.
22. Artim-Esen B, Diz-Kucukkaya R, Inanc M. The significance and management of throm- bocytopenia in antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17(3):14.
23. Chighizola CB, Meroni PL. Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment. Curr Rheumatol Rep. 2018;20(7):44.
24. Zohoury N, Bertolaccini ML, Rodriguez- Garcia JL, et al. Closing the Serological Gap in the Antiphospholipid Syndrome: The Value of "Non-criteria" Antiphospholipid Antibodies. J Rheumatol. 2017;44(11):1597- 1602.
25. Litvinova E, Darnige L, Kirilovsky A, et al. Prevalence and Significance of Non-conven- tional Antiphospholipid Antibodies in Patients With Clinical APS Criteria. Front Immunol. 2018;9:2971.
26. Zhang S, Wu Z, Zhang W, et al. Clinical per- formance of non-criteria antibodies to phos- pholipids in Chinese patients with antiphos- pholipid syndrome. Clin Chim Acta. 2019;495:205-209.
27. Mekinian A, Bourrienne MC, Carbillon L, et
al. Non-conventional antiphospholipid anti-
bodies in patients with clinical obstetrical
APS: Prevalence and treatment efficacy in 236.
pregnancies. Semin Arthritis Rheum.
2016;46(2):232-237.
28. Brusch A. The Significance of Anti-Beta-2-
Glycoprotein I Antibodies in Antiphospholipid Syndrome. Antibodies (Basel). 2016;5(2).
42. Billoir P, Miranda S, Abboud J, et al. [Which place of antiphosphatidylethanolamine anti- bodies research in seronegative antiphos- pholipid syndrome suspicion?]. Rev Med Interne. 2019;40(6):351-354.
43. Bertolaccini ML, Amengual O, Atsumi T, et al. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011;20(2):191-
29. Serrano M, Martinez-Flores JA, Norman GL,
et al. The IgA Isotype of Anti-beta2 Glycoprotein I Antibodies Recognizes
Epitopes in Domains 3, 4, and 5 That Are
Located in a Lateral Zone of the Molecule (L-
Shaped). Front Immunol. 2019;10:1031. 205.
30. Lakos G, Favaloro EJ, Harris EN, et al. International consensus guidelines on anti- cardiolipin and anti-beta2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012;64(1):1-10.
31. Meijide H, Sciascia S, Sanna G, Khamashta MA, Bertolaccini ML. The clinical relevance of IgA anticardiolipin and IgA anti-beta2 gly- coprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev. 2013;12(3):421-425.
32. Cousins L, Pericleous C, Khamashta M, et al. Antibodies to domain I of beta-2-glycopro- tein I and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospho- lipid syndrome. Ann Rheum Dis. 2015;74(1):317-319.
33. Murthy V, Willis R, Romay-Penabad Z, et al. Value of isolated IgA anti-beta2 -glycopro- tein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum. 2013;65(12):3186-3193.
34. Pericleous C, Ferreira I, Borghi O, et al. Measuring IgA Anti-beta2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. Plos One. 2016;11(6):e0156407.
35. Ruiz-Garcia R, Serrano M, Martinez-Flores JA, et al. Isolated IgA anti- beta2 glycopro- tein I antibodies in patients with clinical cri- teria for antiphospholipid syndrome. J Immunol Res. 2014;2014:704395.
36. Tortosa C, Cabrera-Marante O, Serrano M, et al. Incidence of thromboembolic events in asymptomatic carriers of IgA anti ss2 glyco- protein-I antibodies. PloS One. 2017;12(7): e0178889.
37. Sanmarco M, Boffa MC. Antipho- sphatidylethanolamine antibodies and the antiphospholipid syndrome. Lupus. 2009;18 (10):920-923.
38. Berard M, Chantome R, Marcelli A, Boffa MC. Antiphosphatidylethanolamine anti- bodies as the only antiphospholipid anti- bodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol. 1996;23(8):1369-1374.
39. Sanmarco M, Alessi MC, Harle JR, et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost. 2001;85(5):800-805.
40. Sanmarco M, Gayet S, Alessi MC, et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost. 2007;97(6):949-954.
41. Gris JC, Quere I, Sanmarco M, et al. Antiphospholipid and antiprotein syn- dromes in non-thrombotic, non-autoim- mune women with unexplained recurrent primary early foetal loss. The Nimes
44. Katsuragawa H, Kanzaki H, Inoue T, et al. Monoclonal antibody against phos- phatidylserine inhibits in vitro human tro- phoblastic hormone production and inva- sion. Biol Reprod. 1997;56(1):50-58.
45. Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid anti- bodies. Fertil Steril. 1996;66(4):540-546.
46. Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril. 2010;93(4): 1234-1243.
47. Ortona E, Capozzi A, Colasanti T, et al. Vimentin/cardiolipin complex as a new anti- genic target of the antiphospholipid syn- drome. Blood. 2010;116(16):2960-2967.
48. Musaelyan A, Lapin S, Nazarov V, et al. Vimentin as antigenic target in autoimmuni- ty: A comprehensive review. Autoimmun Rev. 2018;17(9):926-934.
49. Conti F, Capozzi A, Truglia S, et al. The mosaic of "seronegative" antiphospholipid syndrome. J Immunol Res. 2014;2014: 389601.
50. Truglia S, Capozzi A, Mancuso S, et al. A Monocentric Cohort of Obstetric Seronegative Anti-Phospholipid Syndrome. Front Immunol. 2018;9:1678.
51. Sciascia S, Sanna G, Murru V, et al. Anti-pro- thrombin (aPT) and anti-phosphatidylser- ine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospho- lipid syndrome. A systematic review. Thromb Haemost. 2014;111(2):354-364.
52. Vaarala O, Puurunen M, Manttari M, et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost. 1996;75(3):456-459.
53. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000;43(9): 1982-1993.
54. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2- glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005;3(6): 1231-1238.
55. Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict throm- bosis in patients with systemic lupus erythe- matosus: a 15-year longitudinal study. J Thromb Haemost. 2007;5(6):1158-1164.
56. Heikal NM, Jaskowski TD, Malmberg E, et al. Laboratory evaluation of anti-phospho- lipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort. Clin Exp Immunol. 2015;180(2):218-226.
57. Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA. Antiprothrombin anti-
Obstetricians and Haematologists Study--
NOHA. Thromb Haemost. 2000;84(2):228-
haematologica | 2020; 105(3)
571